A Phase II study conducted over fifty-two weeks shows that personalized rTMS targeting the Default Mode Network significantly slows the progression of Alzheimer’s disease while improving both cognitive and daily functions without any significant side effects.
According to a recent Phase II clinical research, Alzheimer’s disease development can be markedly slowed by focused magnetic stimulation, such as that employed in conjunction with repetitive transcranial magnetic stimulation. In individuals with mild-to-moderate Alzheimer’s disease, this is a randomized, open-label evaluation of customized rTMS to the brain’s Default Mode Network. At 52 weeks, behavioral problems, daily activities, and cognitive abilities were improved without any significant side effects.
It can put rTMS at the front lines to enhance the life quality and management of Alzheimer’s disease. A 52-week Phase II demonstrates that this tailored rTMS, which focuses on the DMN, indeed significantly reduces the progression of Alzheimer’s disease that, as a consequence, improves cognitive function and daily activity without causing major side effects.
